Bioworld Financial Watch articles from January 2004

Bioworld Financial Watch archives from January 2004

Year of consolidation ends; industry left on 'knife edge'.
January 5, 2004... From most indications, the industry is on the march again after a solid 2003, and the coming year promises even more excitement--which means more competition, especially in key therapeutic areas. The year, after a lackluster 2002, was...

Biotechnology company deals with other biotechnology companies: collaborations, agreements, equity participation: Oct. 24.-Dec. 30, 2003 (#).
January 5, 2004... Biotechnology Company Deals With Other Biotechnology Companies: Collaborations, Agreements, Equity Participation: Oct. 24.-Dec. 30, 2003 (#) Company * Company * Type/Product Area (Country; ...

Biotechnology company deals with miscellaneous companies: collaborations, agreements, equity participation: Oct. 24-Dec. 30, 2003 (#).
January 5, 2004... Biotechnology Company Deals With Miscellaneous Companies: Collaborations, Agreements, Equity Participation: Oct. 24-Dec. 30, 2003 (#) Company * Company * Type/Product Area (Country; Symbol) Biotique ...

Manufacturing, marketing and distribution agreements between biotech companies: Oct. 24-Dec. 30, 2003 (#).
January 5, 2004... Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: Oct. 24-Dec. 30, 2003 (#) Company * Company * Product (Country; (Country; Symbol) Symbol) ...

Biotech--biotech collaborations: modified and terminated agreements: Oct. 24-Dec. 30, 2003 (#).
January 5, 2004... Biotech--Biotech Collaborations: Modified And Terminated Agreements: Oct. 24-Dec. 30, 2003 (#) I. MODIFIED AGREEMENTS Company * Company * Change from original (Country; (Country; agreement...

BioWorld stock report for public biotechnology companies.
January 5, 2004... BioWorld Stock Report For Public Biotechnology Companies Company Symbol Close Close %Change 12/23 12/31 WK YTD Aastrom Biosci ASTM 1.28 1.33...

Hopes flag for new Fuzeon; HIV analyst doubts prospects.
January 12, 2004... When the FDA approved Fuzeon in March, there was jubilation not only by Trimeris Inc. and E Hoffmann-La Roche Ltd., but among AIDS fighters around the world. Fuzeon (enfuvirtide), a first-in-class fusion inhibitor for HIV-1, won approval...

Public financing of biotechnology: December 2003.
January 12, 2004... Public Financing of Biotechnology: December 2003 I. COMMENCED TRADING IN DECEMBER Company Date Date Shares/ (Symbol) Filed Comm. Units(M) INITIAL...

Other financings of public biotechnology companies: December 2003.
January 12, 2004... Other Financings Of Public Biotechnology Companies: December 2003 TOTAL: $1,773.93M Company Type Of Number Of Amount (Symbol) (#) Financing Shares, Units Raised ...

Venture capital and corporate investments in biotechnology companies: December 2003.
January 12, 2004... Venture Capital And Corporate Investments In Biotechnology Companies: December 2003 I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $220.29M Company Location Date Amt. (M) Applied ...

BioWorld stock report for public biotechnology companies.
January 12, 2004... BioWorld Stock Report For Public Biotechnology Companies Company Symbol Close Close 12/31 1/09 Theratechnologies TH 3.7 3.53 Aastrom...

'Cloud of ignorance' looming over drug-research chemistry.
January 19, 2004... SAN FRANCISCO -- Biotechnology's famed "H&Q" meeting every January is known less as a hotbed of ideas than the place where financiers come together with biotechnology leaders for dealmaking--but one panel discussion challenged at least some...

Clinical trial update: December 2003.
January 19, 2004... Clinical Trials Update: December 2003 Company * Product Description (Country; Symbol) AUTOIMMUNE Corixa Corp. PVAC Immunotherapeutic based (CRXA)and ...

Non-U.S. Clinical trials, regulatory submissions, recommendations and approvals: December 2003.
January 19, 2004... Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: December 2003 Company * Product Description (Country; Symbol) AUTOIMMUNE 4SC AG * SC12267 Small...

FDA submissions, approvals and other actions: December 2003.
January 19, 2004... FDA Submissions, Approvals And Other Actions: Dec-03 Company * Product Description (Country; Symbol) AUTOIMMUNE La Jolla Riquent B-cell toleragen; Pharmaceutical ...

BioWorld stock report for public biotechnology companies.
January 19, 2004... BioWorld Stock Report For Public Biotechnology Companies %Change Company Symbol Close Close 1/9 1/16 WK YTD...

London stock exchange.
January 19, 2004... LONDON STOCK EXCHANGE Company Symbol 1/9 1/16 %WK %YTD Acambis ACM 303 315 3.96 13.72 Antisoma ASM 38.5 38.75 0.65 34.78...

Toronto stock exchange.
January 19, 2004... TORONTO STOCK EXCHANGE Company Symbol 1/9 1/16 %WK %YTD Adherex AHX 0.54 0.5 -7.41 16.28 Angiotech Pharma ANP 57.5 64.07 11.43 19.60...

Answering the call for products, ViroPharma shifting gears again.
January 26, 2004... It was deja vu, but not the same. In August 2002, when ViroPharma Inc.'s deal with Aventis Pharmaceuticals Inc. to develop Picovir (pleconaril) for the common cold ended--the arrangement was terminated by mutual consent, and ViroPharma's...

U.S. public offering performance by underwriter: Jan. 1-Dec. 31, 2003 *.
January 26, 2004... U.S. Public Offering Performance By Underwriter: Jan. 1-Dec. 31, 2003 * Underwriter Biotechnology Date Offering Company Priced Price Per ...

BioWorld stock report for public biotechnology companies.
January 26, 2004... BioWorld Stock Report For Public Biotechnology Companies Company Symbol Close Close % Change Vol 1/16 1/23 WK YTD (000) Aastrom Biosci ASTM 1.59 1.65 ...